Laurus Labs Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Laurus Labs de 49.1% y 14.1% por año respectivamente. Se prevé que el BPA crezca en un 49.5% al año. Se espera que la rentabilidad financiera sea de 15.6% en 3 años.

Información clave

47.7%

Tasa de crecimiento de los beneficios

47.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.3%
Tasa de crecimiento de los ingresos	13.4%
Rentabilidad financiera futura	16.3%
Cobertura de analistas	Good
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jan 27

Recent updates

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40

Apr 28

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jan 27

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Dec 01

Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year

Oct 22

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well

Jul 06

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20

Apr 30

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Dec 18

Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 27

I Ran A Stock Scan For Earnings Growth And Laurus Labs (NSE:LAURUSLABS) Passed With Ease

Nov 12

Laurus Labs (NSE:LAURUSLABS) Has Affirmed Its Dividend Of ₹0.80

Oct 30

A Look At The Intrinsic Value Of Laurus Labs Limited (NSE:LAURUSLABS)

Oct 05

Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?

Aug 10

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Jul 23

Is Laurus Labs Limited (NSE:LAURUSLABS) Worth ₹547 Based On Its Intrinsic Value?

Jun 06

We Think That There Are Issues Underlying Laurus Labs' (NSE:LAURUSLABS) Earnings

May 06

Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?

May 05

We Think Laurus Labs (NSE:LAURUSLABS) Can Stay On Top Of Its Debt

Mar 16

Could The Laurus Labs Limited (NSE:LAURUSLABS) Ownership Structure Tell Us Something Useful?

Mar 01

Shareholders Are Raving About How The Laurus Labs (NSE:LAURUSLABS) Share Price Increased 331%

Feb 16

There's A Lot To Like About Laurus Labs' (NSE:LAURUSLABS) Upcoming ₹0.40 Dividend

Feb 03

Previsiones de crecimiento de beneficios e ingresos

NSEI:LAURUSLABS - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	74,728	9,022	5,000	11,735	5
3/31/2026	68,277	7,303	2,397	9,983	14
3/31/2025	58,957	4,254	3,653	9,442	14
3/31/2024	50,408	1,606	-126	6,657	N/A
12/31/2023	49,821	1,879	N/A	N/A	N/A
9/30/2023	53,320	3,678	2,870	12,248	N/A
6/30/2023	56,834	5,637	N/A	N/A	N/A
3/31/2023	60,406	7,901	37	9,939	N/A
12/31/2022	60,845	9,176	N/A	N/A	N/A
9/30/2022	55,684	8,683	13	8,393	N/A
6/30/2022	51,960	8,374	N/A	N/A	N/A
3/31/2022	49,356	8,275	343	9,111	N/A
12/31/2021	49,227	8,937	N/A	N/A	N/A
9/30/2021	51,823	10,128	-1,705	7,112	N/A
6/30/2021	51,177	10,532	N/A	N/A	N/A
3/31/2021	48,135	9,836	442	7,330	N/A
12/31/2020	42,407	7,971	N/A	N/A	N/A
9/30/2020	36,819	5,977	1,548	5,427	N/A
6/30/2020	32,555	4,120	N/A	N/A	N/A
3/31/2020	28,317	2,553	1,252	3,474	N/A
12/31/2019	26,277	1,883	N/A	N/A	N/A
9/30/2019	24,276	1,326	1,613	3,538	N/A
6/30/2019	23,035	923	N/A	N/A	N/A
3/31/2019	22,919	938	434	2,977	N/A
12/31/2018	22,170	957	N/A	N/A	N/A
9/30/2018	21,665	1,127	N/A	N/A	N/A
6/30/2018	21,168	1,453	N/A	N/A	N/A
3/31/2018	20,562	1,676	-486	3,425	N/A
12/31/2017	19,687	1,917	N/A	N/A	N/A
9/30/2017	19,954	2,019	N/A	N/A	N/A
6/30/2017	19,733	2,014	N/A	N/A	N/A
3/31/2017	19,046	1,881	N/A	3,320	N/A
3/31/2016	17,776	1,337	N/A	1,820	N/A
3/31/2015	13,266	684	N/A	-647	N/A
3/31/2014	11,597	972	N/A	1,212	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (49.1% al año) de LAURUSLABS es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (49.1% al año) de LAURUSLABS crezcan más rápidamente que el mercado Indian (18% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de LAURUSLABS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (14.1% al año) de LAURUSLABS crezcan más rápidamente que los del mercado Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 14.1% al año) de LAURUSLABS crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de LAURUSLABS sea baja dentro de 3 años (15.6%).

Laurus Labs Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Consensus EPS estimates fall by 34%

Price target increased by 7.2% to ₹371

Consensus EPS estimates fall by 10%

Price target decreased by 11% to ₹382

Price target decreased by 10% to ₹470

Recent updates

Less than half of directors are independent

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40

Final dividend reduced to ₹0.40

Laurus Labs Limited, Annual General Meeting, Jul 11, 2024

Full year 2024 earnings: EPS misses analyst expectations

Laurus Labs Limited Approves Board Changes

Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Consensus EPS estimates fall by 34%

Upcoming dividend of ₹0.40 per share at 0.4% yield

Price target increased by 7.2% to ₹371

Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023

Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023

Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 10%

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023)

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million.

Upcoming dividend of ₹1.20 per share at 0.6% yield

Price target decreased by 11% to ₹382

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to ₹470

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private Limited

Insufficient new directors

Upcoming dividend of ₹0.80 per share

Price target decreased to ₹574

Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022

Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value

Is Laurus Labs (NSE:LAURUSLABS) Using Too Much Debt?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022

Investor sentiment deteriorated over the past week

Laurus Labs (NSE:LAURUSLABS) Has A Somewhat Strained Balance Sheet

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of ₹1.20 per share

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Larger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Laurus Labs Limited to Report Q4, 2022 Results on Apr 28, 2022

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Laurus Labs (NSE:LAURUSLABS) Is Interesting

Price target decreased to ₹563

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Does Laurus Labs (NSE:LAURUSLABS) Have A Healthy Balance Sheet?

Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.80

I Ran A Stock Scan For Earnings Growth And Laurus Labs (NSE:LAURUSLABS) Passed With Ease

Upcoming dividend of ₹0.80 per share

Second quarter 2022 earnings released: EPS ₹3.76 (vs ₹4.53 in 2Q 2021)

Laurus Labs (NSE:LAURUSLABS) Has Affirmed Its Dividend Of ₹0.80

Investor sentiment deteriorated over the past week

A Look At The Intrinsic Value Of Laurus Labs Limited (NSE:LAURUSLABS)

Insider recently sold ₹7.9m worth of stock

Insider recently sold ₹3.2m worth of stock

Insider recently sold ₹3.6m worth of stock

Insider recently sold ₹1.0m worth of stock